

# Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

## PK-8

RRID:CVCL\_4718

Type: Cell Line

### Proper Citation

RRID:CVCL\_4718

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_4718](https://web.expasy.org/cellosaurus/CVCL_4718)

**Proper Citation:** RRID:CVCL\_4718

**Description:** Cell line PK-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Sex unspecified

**Disease:** Pancreatic ductal adenocarcinoma

**Defining Citation:** [PMID:3547771](#), [PMID:11115575](#), [PMID:16912165](#), [PMID:20037478](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#)

**Comments:** Characteristics: Established from a xenograft., Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** PK-8

**Synonyms:** PK8

**Cross References:** BTO:BTO\_0004855, CLO:CLO\_0050112, EFO:EFO\_0006737, ArrayExpress:E-MTAB-2706, BioSample:SAMN03472951, cancercellines:CVCL\_4718, Cosmic:707254, Cosmic:1066177, Cosmic:1644298, DepMap:ACH-002039, EGA:EGAS00001000610, IARC\_TP53:14302, Pharmacodb:PK8\_1269\_2019, RCB:RCB2096, RCB:RCB2700, TKG:TKG 0383, Wikidata:Q54947454

**ID:** CVCL\_4718

**Record Creation Time:** 20220427T221433+0000

**Record Last Update:** 20260815T235542+0000

---

## Ratings and Alerts

No rating or validation information has been found for PK-8.

**Warning:** Discontinued: RCB; RCB2096

Characteristics: Established from a xenograft., Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Cancer research, OF1.

Munekage E, et al. (2021) A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia (New York, N.Y.), 23(9), 939.